Emerald Advisers’s Maravai LifeSciences MRVI Stock Holding History

Emerald Advisers’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,382	Closed	-$362K	–	288
2021 Q3	$362K	Sell	7,382 -348	-5%	-$17K	0.01%	207
2021 Q2	$323K	Hold	7,730	–	–	0.01%	219
2021 Q1	$275K	Sell	7,730 -17,926	-70%	-$594K	0.01%	223
2020 Q4	$720K	Buy	+25,656	New	+$714K	0.02%	175

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Emerald Advisers's MRVI Position: Q4 2021 in Review

Emerald Advisers sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 7,382 shares — an estimated $362K sold.

Emerald Advisers first reported a position in MRVI in Q4 2020 and held it in 4 quarters. The position peaked at $720K in Q4 2020. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

Emerald Advisers reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
Emerald Advisers sold 7,382 Maravai LifeSciences shares in Q4 2021, an estimated $362K.
Emerald Advisers first reported a position in Maravai LifeSciences in Q4 2020 and held it in 4 quarters.
Emerald Advisers's Maravai LifeSciences position peaked at $720K in Q4 2020.
229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on Emerald Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.